• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: ROCHE DIAGNOSTICS ELECSYS INSULIN; IMMUNOREACTIVE INSULIN TEST SYSTEM

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

ROCHE DIAGNOSTICS ELECSYS INSULIN; IMMUNOREACTIVE INSULIN TEST SYSTEM Back to Search Results
Catalog Number 07027559190
Device Problem High Test Results (2457)
Patient Problem No Clinical Signs, Symptoms or Conditions (4582)
Event Date 02/15/2022
Event Type  malfunction  
Event Description
The initial reporter stated they have received questionable test results for one patient tested with elecsys insulin on a cobas 8000 e 801 module.It was asked, but it is not known if any incorrect values were reported outside of the laboratory.The reporter states that the patient showed very high insulin values > 6000 when the patient is under the administration of acrapid insulin.No units of measure were provided for insulin.When the patient is under therapy with lantus and apidra insulins, the insulin values of the patient are very low at 10-20.The serial number of the e 801 analyzer is (b)(4).
 
Manufacturer Narrative
Na.
 
Manufacturer Narrative
Product labeling states: "intended use: immunoassay for the in vitro quantitative determination of human insulin in human serum and plasma." product labeling also states: "samples from patients treated with bovine, porcine or human insulin sometimes contain anti-insulin antibodies.15,9 insulin bound to these antibodies is at least partially recognized by the antibodies used in the elecsys insulin assay.16".As the intended use of the elecsys insulin assay is the determination of human insulin, this may possibly explain the high result when the patient was given actrapid.Actrapid is human insulin.Furthermore, the patient has insulin antibodies.Insulin bound to anti-insulin antibodies are known to be at least partially recognized by the elecsys insulin assay.No sample from the patient was available for further investigation.The investigation could not identify a product problem.The cause of the event could not be determined.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
ELECSYS INSULIN
Type of Device
IMMUNOREACTIVE INSULIN TEST SYSTEM
Manufacturer (Section D)
ROCHE DIAGNOSTICS
9115 hague road
indianapolis IN 46250 0457
Manufacturer (Section G)
ROCHE DIAGNOSTICS GMBH
sandhoferstrasse 116
na
mannheim (baden-wurttemberg) 68305
GM   68305
Manufacturer Contact
michael leslie
9115 hague road
na
indianapolis, IN 46250
3175214343
MDR Report Key13731424
MDR Text Key293080353
Report Number1823260-2022-00655
Device Sequence Number1
Product Code CFP
UDI-Device Identifier04015630940042
UDI-Public04015630940042
Combination Product (y/n)N
Reporter Country CodeGM
PMA/PMN Number
K001104
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Foreign,Health Professional,User Facility
Reporter Occupation Other Health Care Professional
Type of Report Initial,Followup
Report Date 04/11/2022
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received03/11/2022
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Catalogue Number07027559190
Device Lot NumberASKU
Was Device Available for Evaluation? Yes
Is the Reporter a Health Professional? Yes
Date Manufacturer Received03/18/2022
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Is the Device Single Use? No
Is This a Reprocessed and Reused Single-Use Device? No
Patient Sequence Number1
Treatment
ACTRAPID; APIDRA; LANTUS
-
-